Stories
JPMorgan: Hospital Stocks to Compound, CDMO Outlook Strong Amid Expansion
- •Indian healthcare sector, particularly hospitals and CDMOs, attracts strong investor interest, according to JPMorgan's Bansi Desai.
- •Hospital stocks, despite high valuations, are expected to continue compounding at high-teens to 20%+ levels due to stronger growth, improved margins, and healthier balance sheets.
- •The sector's re-rating reflects companies funding expansion through internal accruals, keeping leverage under control, with a significant capacity expansion of 30,000-40,000 beds expected.
- •CDMOs benefit from structural trends like higher outsourcing, supply-chain diversification, and a shift towards complex products.
- •US Section 232 tariffs on generic drugs are currently exempt for two years, but potential impacts could rise significantly from the third year, prompting some pharma companies to increase US manufacturing presence.
Key Questions Answered
According to JPMorgan, Indian hospital stocks are expected to continue compounding at high-teens to 20%-plus levels during their current capacity expansion cycle. Unlike previous cycles, current expansions are largely funded through internal accruals with controlled leverage, and valuations have normalized to around 23-25 times one-year forward EV/EBITDA.
Listed hospital companies in India are projected to add approximately 30,000 to 34,000 hospital beds over the next three to four years. This expansion involves a mixture of greenfield and brownfield facilities, with brownfield projects expected to break even faster.
Most generic drug companies are currently exempt from Section 232 tariffs for the next two years. However, potential impacts could escalate significantly by the third year with tariffs rising to 100%, and potentially up to 200% in the fourth year, leaving pharmaceutical companies in a wait-and-watch mode.
